Aerie Pharma (AERI) PT Raised to $63 at Brean Capital

Brean Capital analyst Difei Yang reiterated a Buy rating and listed its price target on Aerie Pharma (NASDAQ: AERI) to $63.00 (from $48.00) following yesterday's investor day.

Yang commented, "At yesterday’s investor day, Aerie painted a clearer portrait of the current standard of care and competitive glaucoma treatment environment. Management also provided further insight into the recent Mercury 1 data for Roclatan, a closer look at how to measure the effectiveness of glaucoma treatment with added perspective from a former physician, as well as revisited what the company’s future value adding drivers will be and articulated the international strategy. We took the opportunity to dive deeper into our model, taking into account potential future European launches and Japanese clinical trials. As such we reiterate our BUY rating and raise our TP to $63."

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $39.26 yesterday.

You May Also Be Interested In

• ASM International NV (ASM:NA) PT Raised to EUR720 at Citi
• Atlas Copco AB (ATCOA:SS) (ATLKY) PT Raised to SEK150 at RBC Capital
• Entergy Corp (ETR) PT Raised to $118 at BMO Capital